This narrative review examines the application of artificial intelligence and machine learning for prospective adherence risk prediction in patients with chronic diseases globally. The scope encompasses conditions including HIV, tuberculosis, diabetes, hypertension, and mental health disorders, comparing these advanced approaches against traditional adherence monitoring methods. The review does not report a specific sample size or follow-up duration, as these details were not reported in the source material.
The authors highlight that discrimination metrics (AUC) for these models range from 0.70 to 0.95, indicating performance superior to traditional risk stratification. However, the review explicitly cautions that these AUC values should not be interpreted as results of formal comparison or quantitative synthesis across diseases or modeling approaches. Key secondary outcomes discussed include clinical translation barriers, external validation status, algorithmic bias, interpretability, data privacy, and implementation challenges.
Significant limitations identified by the authors include limited external validation and algorithmic bias affecting marginalized populations. Inadequate interpretability and data privacy concerns further complicate adoption. The review notes substantial implementation challenges, particularly within resource-limited health systems. Consequently, while the practice relevance involves enabling anticipatory, resource-efficient interventions, the evidence remains observational and does not establish causal benefits or specific safety profiles for these technologies.
View Original Abstract ↓
Medication non-adherence affects 40%–50% of chronic disease patients globally, causing preventable morbidity and substantial healthcare costs. Traditional adherence monitoring approaches are retrospective and reactive, limiting timely intervention. Artificial intelligence and machine learning offer novel approaches for prospective adherence risk prediction, enabling anticipatory, resource-efficient interventions. This narrative review synthesizes current evidence on AI-based non-adherence prediction across chronic diseases including HIV, tuberculosis, diabetes, hypertension, and mental health disorders. Machine learning models integrating heterogeneous data sources electronic health records, pharmacy refill patterns, sociodemographic variables, and healthcare utilization achieve discrimination metrics (AUC 0.70–0.95) superior to traditional risk stratification. These AUC values are reported descriptively to reflect model discrimination within individual studies and should not be interpreted as results of formal comparison or quantitative synthesis across diseases or modeling approaches. However, significant barriers constrain clinical translation: limited external validation, algorithmic bias affecting marginalized populations, inadequate interpretability, data privacy concerns, and substantial implementation challenges in resource-limited health systems. Future research priorities include rigorous multicenter external validation, model development in low- and middle-income countries, advancement of interpretable architectures, and prospective randomized trials evaluating clinical outcomes. Responsible AI deployment requires participatory governance, health equity prioritization, and maintenance of clinician oversight throughout implementation. This review critically evaluates AI potential while emphasizing prerequisites for equitable, ethical, and clinically meaningful adherence prediction in global health contexts.